RxDoctor Payments Data

Marios Giannakis, MD

Medical Oncology · Boston, MANPI 1417185729

Payments from drug & device makers

What this record shows

This record is dominated by grants: $66,667 of the $70,728 with a category attached, or 94.3%. Genentech, Inc. accounts for 94.3% of it on its own, with 2 other manufacturers making up the rest.

$70,728in general payments, 2019–2025

Across 4 payments — averaging $17,682 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$67K
  • AstraZeneca$2K
  • Chromacode, Inc$2K
$553,756in research payments, 2019–2025

Across 13 payments — averaging $42,597 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$548K
  • Novartis$6K

What the payments were for

  • Consulting fees$2,0553%
  • Speaking & faculty fees$2,0003%
  • Grants$66,66794%
  • Food & beverage$60%

General payments by program year

19
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.1$66,667
AstraZeneca2$2,061
Chromacode, Inc1$2,000

How this compares

$70,728 in reported general payments places this provider in the 80th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$6,483
Medicare patients
23
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →